Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease
MONDO:0020332Systemic mastocytosis with an associated clonal hematological non-mast cell lineage disease is a form of systemic mastocytosis (SM) associated with malignancy (other than mast cell leukemia).
Also known as: SM-AHN, SM-AHNMD, SMAHN, systemic mastocytosis with an associated haematological neoplasm, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), systemic mastocytosis with an associated hematological neoplasm, systemic mastocytosis with an associated hematological neoplasm (SM-AHN), systemic mastocytosis with associated clonal haematological non-mast-cell lineage disease
1857 clinical trials for this condition and its sub-types, 4 tagged with Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for rare blood cancer: experimental drug targets mast cells
Disease control Recruiting nowThis study tests an experimental drug called CGT9486 (bezuclastinib) in people with advanced systemic mastocytosis, a rare and serious blood disorder. The drug aims to control the disease by blocking a key protein that drives abnormal mast cell growth. About 140 adults with aggre…
Phase 2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for mastocytosis patients: expanded access to bezuclastinib
Disease control Expanded accessThis program provides the investigational drug bezuclastinib to adults with systemic mastocytosis who have failed or cannot tolerate standard treatments. Participants must be at least 18 years old and able to swallow tablets. The goal is to offer a potential treatment option when…
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to tackle tough blood cancer
Disease control Recruiting nowThis early-phase study tests a combination of two drugs, avapritinib and decitabine, for people with a rare blood cancer called systemic mastocytosis with an associated hematologic neoplasm (SM-AHN). The goal is to find a safe dose that can control both parts of the disease. Abou…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC